Agilent Technologies, Inc. A
Healthcare · Diagnostics & Research · United States · S&P 500
Based on the available data, Agilent Technologies, Inc. gets an algorithmic score of 66/100. It trades at 175.03 $, with a bullish technical trend (RSI 76.4) and 33.3% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- High ROE (21.0%): generates strong profit on equity.
- Meaningful dividend (58.00%).
Weaknesses
- —
Fundamentals
| P/E | 34.45 |
| Forward P/E | 25.90 |
| PEG | 1.37 |
| P/B | 6.70 |
| EV/EBITDA | 24.87 |
| P/S | 6.69 |
| ROE % | 20.97 |
| ROA % | 8.63 |
| Gross margin % | 53.65 |
| Operating margin % | 25.56 |
| Net margin % | 19.53 |
| Revenue growth % (y/y) | 8.10 |
| Earnings growth % (y/y) | 8.50 |
| Revenue CAGR % | 0.48 |
| Earnings CAGR % | 1.29 |
| Debt/Equity % | 56.34 |
| Current ratio | 2.05 |
| FCF yield % | 2.33 |
| Dividend yield % | 58.00 |
| Payout % | 19.98 |
Returns
| 1 month | +13.8 % |
| 3 months | +31.8 % |
| 6 months | +56.9 % |
| YTD | +27.6 % |
| 1 year | +43.0 % |
| 3 years | +60.7 % |
| 5 years | +5.8 % |
Risk
| 1-year volatility | 33.3 % |
| Beta | 0.97 |
| 5-year max drawdown | -41.0 % |
| Sharpe 1A | 1.12 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.